新葡萄88833官网AMG

Abstract

Chemistry designed for living systems, termed “bioorthogonal chemistry”, has enabled new approaches for biological research.  We initially developed these reactions for applications to glycobiology, which led to the discovery of new roles for cell-surface glycans in cancer and new types of glycoconjugates including glycoRNA.  Bioorthgonal and related click chemistry reactions are now impacting drug development by enabling new approaches to bioconjugate drugs (e.g., antibody-drug conjugates).  This presentation will overview the history of the field and recent examples of clinical translation.

Biography

Carolyn Bertozzi is the Anne T. and Robert M. Bass Professor of Chemistry and Professor of Chemical & Systems Biology and Radiology (by courtesy) at Stanford University, and an Investigator of the Howard Hughes Medical Institute. She completed her undergraduate degree in Chemistry from Harvard University in 1988 and her Ph.D. in Chemistry from UC Berkeley in 1993. After completing postdoctoral work at UCSF in the field of cellular immunology, she joined the UC Berkeley faculty in 1996. In June 2015, she joined the faculty at Stanford University coincident with the launch of Stanford's Sarafan ChEM-H Institute. Prof. Bertozzi's research interests span the disciplines of chemistry and biology with an emphasis on developing new therapeutic modalities that target disease-related glycobiology. She founded the field of bioorthogonal chemistry, for which she shared the 2022 Nobel Prize in Chemistry. She is an elected member of the Institute of Medicine, National Academy of Sciences, National Academy of Inventors and American Academy of Arts and Sciences.